dismiss

Clean Sweep Live Auction on Wed. May 1st. Click to view the full inventory

DOTmed Home MRI Oncology Ultrasound Molecular Imaging X-Ray Cardiology Health IT Business Affairs
News Home Parts & Service Operating Room CT Women's Health Proton Therapy Endoscopy HTMs Pediatrics
SEARCH
Posição atual:
>
> This Story


Início de uma sessão ou Registo to rate this News Story
Forward Printable StoryPrint Comment
advertisement

 

advertisement

 

Molecular Imaging Homepage

Louisiana getting $14 million Center for Molecular Imaging and Therapy Increasing research opportunities, collaboration and radiopharmaceuticals

DOE transfers land to Coquí Pharma for isotope production facility Will be used primarily to produce Mo-99

PET uncovers abnormal tau deposits associated with CTE in live subjects May enable diagnosis of CTE in living people one day

Amyloid PET scans help with Alzheimer's clinical management New insights from the 11,000 patient IDEAS study

United Imaging's total-body PET scanner shows promise in four new studies Faster scans, lower dose and 'a level of detail never seen in PET'

NorthStar buys IBA electron accelerators for Mo-99 production Will increase production capacity and efficiencies

RadioMedix and Vect-Horus to develop brain theranostic agent for brain cancer Provide diagnosis and treatment of Glioblastoma Multiforme (GBM)

NIH awards $1.8 million to Magnetic Insight for neurovascular MPI Detects magnetic nanoparticle tracers, enables deep-tissue imaging

DOE to cut Moly-99 deals with four US firms Could be as much as $15 million per company, with partners matching awarded amounts

Women's brains appear three years younger than men's at the same age: PET study A machine-learning algorithm assisted with the analysis

Cerveau Technologies has partnered with
Ionis Pharmaceuticals to evaluate its
novel tau imaging agent

Cerveau Technologies partners with Ionis Pharmaceuticals

por John R. Fischer , Staff Reporter
Cerveau Technologies Inc. has agreed to supply one of its investigational imaging agents for use in neurodegenerative disease research studies overseen by Ionis Pharmaceuticals Inc., as part of a research collaboration agreement.

Used in PET scans, [F-18]MK-6240 is designed to evaluate the status and progression of neurofibrillary tangles (NFTs), which consist of aggregated tau protein in the brain, a hallmark of Alzheimer’s disease and other neurodegenerative conditions.

Story Continues Below Advertisement

Servicing GE Nuclear Medicine equipment with OEM trained engineers

We offer full service contracts, PM contracts, rapid response, time and material,camera relocation. Nuclear medicine equipment service provider since 1975. Click or call now for more information 800 96 NUMED



“We are thrilled by the opportunity to work with Ionis to foster development of this exciting technology,” Rick Hiatt, president and CEO of Cerveau Technologies, said in a statement. “Consistent with our vision, we will make novel imaging biomarkers and supporting informatics available to our pharmaceutical industry and academic partners, providing access to the broader scientific community.”

News of the partnership builds upon Cerveau’s recent decision to branch out its production network to six new U.S. locations to enhance access to and opportunities for research on [F-18]MK-6240, as well as another agreement with Kobe Hospital in Japan for multiple studies on the use of the agent.

The two plan to assess the effect of the [F-18]MK-6240 as a biomarker as part of a collaboration focused on the use of therapies and their impact on the progression of neurodegenerative diseases in humans, such as Alzheimer’s.

“There is a critical need for sensitive biomarkers for early in-life diagnosis of neurodegenerative diseases to allow for more appropriate staging of disease states, and measuring the effect of disease-modifying therapeutics,” Frank Bennett, SVP research of Ionis Pharmaceuticals, said in a statement. “Imaging agents such as [F-18]MK-6240 are important tools for accelerating the development of our disease modifying antisense therapies.”

Derived as a collaboration between Enigma Biomedical Group Inc. and Sinotau Pharmaceutical Group, Cerveau aims to develop diagnostics and technology for patients suffering from neurodegenerative diseases such as Alzheimer’s.

An RNA-targeted drug discovery and development enterprise, Ionis focuses on developing pharmaceuticals for patients with the highest unmet medical needs, including those with severe and rare diseases.

Cerveau and Ionis did not respond for comment.

Molecular Imaging Homepage


You Must Be Logged In To Post A Comment

Anuncie
Aumente a Sua Perceção da Marca
Leilões + Vendas Privadas
Comece
O mais melhor preço
Comprar Equipamento/Peças
Encontre
O preço o mais baixo
Notícia diária
Leia
A notícia a mais atrasada
Diretório
Browse tudo
DOTmed Usuários
Ética no DOTmed
Veja o nosso
Programa das éticas
O ouro parte o programa do vendedor
Receba PH
Pedidos
Programa do negociante do serviço do ouro
Receba RFP/PS
Pedidos
Fornecedores de Healthcare
Veja tudo
Ferramentas de HCP
Trabalhos/Treinamento
Achado/suficiência
Um trabalho
Parts Hunter +EasyPay
Comece as peças
Citações
Certificado recentemente
Vista recentemente
Usuários certificados
Recentemente Rated
Vista recentemente
Usuários certificados
Central Rental
Equipamento do aluguel
Para menos
Vender Equipamentos/Peças
Comece
A maioria de dinheiro
Preste serviços de manutenção ao Forum dos técnicos
Ajuda do achado
E conselho
Simples RFP
Comece o equipamento
Citações
Mostra de comércio virtual
Serviço do achado
Para o equipamento
O acesso e o uso deste local são sujeitos aos termos e às condições do nosso OBSERVAÇÃO LEGAL & OBSERVAÇÃO DA PRIVACIDADE
Propriedade de e proprietário DOTmeda .com, Inc. Copyright ©2001-2019 DOTmed.com, Inc.
TODOS OS DIREITOS RESERVADOS